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Abstract
Background: Thrombospondin-related anonymous protein (TRAP) is essential for sporozoite
motility and for liver cell invasion. TRAP is a type 1 membrane protein that possesses multiple
adhesive domains in its extracellular region.
Methods:  Plasmodium falciparum TRAP (PfTRAP) and its subdomains were expressed in a
mammalian expression system, and eleven different mutants generated to study interaction of
PfTRAP with liver cells. Binding studies between HepG2 cell extracts and PfTRAP were performed
using co-immunoprecipitation protocols.
Results: Five different amino acid residues of PfTRAP that are involved in liver cell binding have
been identified. These PfTRAP mutants bound to heparin like the wild type PfTRAP thereby
suggesting a non-heparin mediated binding of PfTRAP to liver cells. Three Src family proteins -Lyn,
Lck and CrkL which interact with PfTRAP are also identified. Liver cell extracts and
immunoprecipitated Src family kinases phosphorylated PfTRAP at multiple sites. An analysis of
multiple TRAP sequences revealed Src homology 3 domain (SH3) binding motifs.
Conclusion: Binding of PfTRAP to SH3-domain containing proteins like Src-family kinases and
their ability to phosphorylate PfTRAP suggests a novel role for PfTRAP in cell signaling during
sporozoite invasion and homing inside the liver cells. These data shed new light on TRAP-liver cell
interactions.
Background
Malaria is a major parasitic disease that claims more than
two million lives and causes more than 500 million clini-
cal cases every year [1]. Despite continuous efforts to con-
trol malaria, it remains a major health problem in the
tropical world, mainly due to Plasmodium falciparum.
Since the search for a malaria vaccine remains elusive,
there is a constant and pressing need to identify new drug
and vaccine targets. Malaria infection in humans starts
when infected female Anopheles  mosquitoes take their
blood meal and inject sporozoites into the host (human)
skin. Although, it remains unclear how sporozoites reach
hepatocytes, experimental evidence suggests role of vari-
ous molecules for successful infection that includes com-
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ponents both from the host and the parasite.
Apicomplexans lack a classical locomotory organelles like
flagellum or cilium but show an actin based locomotion
called gliding motility [2,3]. Secretory organelles, includ-
ing rhoptries and dense granules, are present in apicompl-
exans which secrete a number of proteins required for
infectivity, motility and invasion [4]. Two important sur-
face molecules that play key roles in liver cell infection are
the circumsporozoite protein (CS) and the thrombospon-
din-related anonymous protein (TRAP). CS is a multi-
functional protein that is involved in sporozoite
development in mosquitoes, invasion into mosquito sali-
vary gland and into human liver cells [5-11]. TRAP is
stored in the micronemes [12] and becomes surface
exposed at the sporozoite anterior tip when parasite
comes in contact with host cells [13]. TRAP also plays an
important role in liver cell invasion of sporozoites by
helping sporozoites in gliding motility and in recognition
of host receptors on the mosquito salivary gland and
hepatocytes [14-18].
The  P. falciparum TRAP (PfTRAP) extracellular domain
(ECD) consists of three domains/motifs that include the
A-domain (similar to the A-or I-domain which is found in
integrins), the TSP (thrombospondin repeat motif, a
heparin-binding module, also called the RII region) and a
proline-rich segment at the C-terminus. Sequence analysis
of the proline-rich segment revealed the presence of SH3-
domain binding PxxP motifs in Plasmodium  TRAPs. To
understand the role(s) for multiple adhesive domains of
PfTRAP, its extracellular domain (ECD) and subdomains
were expressed using a mammalian expression system.
Five crucial amino acid residues -C55, D162, C205, R307
(of RGD) and S416, that are likely to be involved in TRAP-
liver cell interactions, were mapped. Surprisingly, most of
these mutants did not show reduction in heparin-binding
abilities, suggesting that the significant reduction in TRAP
mutants binding to HepG2 cells was not due to loss of
heparin binding ability. Interaction of PfTRAP with host
SH3-domain containing tyrosine kinases -CrkL, Lck and
Lyn that belong to the c-Src kinase family was also stud-
ied. Immunoprecipitation experiments indicated that
each of these three tyrosine kinases and total HepG2 cell
extract were able to phosphorylate PfTRAP at multiple
sites. Together, these data indicates non-heparin based
interaction of PfTRAP to liver cells and also suggests a role
for PfTRAP in signaling during sporozoite invasion of
hepatocytes.
Methods
Cloning of PfTRAP and its subdomains in mammalian 
expression vector pHL
PfTRAP A-domain, A+RII, A+RII+RGD and ECD were PCR
amplified using forward primer 5'GCACATACCGGTAGA-
GATGTGCAAAACAATATAGTG 3' and reverse primers
5'GCACCCTCGAGACTATCCACTACCACTACCACTAC-
CTTTGCTGTCCATGCAGAATCAGCATAC 3' (for A
domain), 5'GCACCCTCGAGACTATCC ACTACCACTAC
CACTACCTTAACATCTAATGGTTCCCATTTTGG3'
(forA+RII), 5'GCACCCTCGAGACTATCCACTACCACTAC
CACTACCTTTGGTTTTTGGACAGAAGAATTATC3'
(forA+RII+RGD) and 5'GCACCCTCGAGACTATCCA
CTACCACTACCACTACCTTTTTATATTTATTATTTTTTT 3'
(for ECD). The amplified PCR fragments were digested
with AgeI and XhoI and fragments were cloned in pHL vec-
tor [19]. Recombinant clones were identified by restric-
tion digestion of plasmid DNA obtained from colonies
after transformation of the ligation mix. The clones were
further confirmed by automated DNA sequencing.
Expression analysis of PfTRAP subdomains in HEK 293 
cells
Three clones each of PfTRAP and its fragments were
selected. DNA (2 µg) of each of these were added to 100
µl of incomplete DMEM. PEI (6 µg) was then added to
each mix and incubated at room temperature for 15 min.
In parallel, HEK 293 cells at 60–70 percent confluency (in
35-mm tissue culture plates) were washed with PBS to
remove serum. Cells in the incomplete DMEM were incu-
bated with transfection mix for 3–4 h at 37°C in a
humidized CO2 incubator, and 2 ml of expression media
(iDMEM pH7.2+2%FBS+1× non-essential amino acid+
1× antibiotic and antimycotic+2 mM L-glutamine) were
added to each well. The media that contained secreted
protein were harvested four days post-transfection and
cleared by centrifugation at 5,000 rpm. Expression of
recombinant proteins was detected using western blotting
with anti-penta-his and anti-PfTRAP antibodies.
Purification of PfTRAP subdomains from HEK-293 cells
Large-scale transfections (~4 litres) were carried out for
pHL-PfTRAP constructs. The media were harvested from
each plate and centrifuged at 5,000 rpm for 20 min at
4°C. Supernatants were filtered through 0.2 µ-filter mem-
brane and concentrated in a diafiltration unit (Millipore)
containing filtration cartridge of 10 kDa cut off. The
media were dialyzed against PBS supplemented with 500
mM NaCl (pH 8.0) to remove chelators from the media.
The harvested media containing PfTRAP proteins were
passed through chelating column (Amersham Bio-
sciences) that had been charged with Ni2+ and pre-equili-
brated with the dialysis buffer (PBS supplemented with
500 mM NaCl pH 8.0). Columns were washed with 10
column volumes of dialysis buffer, and then with 30 and
50 mM imidazole buffer. The bound proteins were eluted
in 200 mM imidazole elution buffer. Eluted protein frac-
tions were further concentrated in a 10 kDa centriprep
(vivaspin) and subjected to gel exclusion chromatography
(GPC). Purity of the proteins was assessed on 12% SDS-Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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PAGE. Similar protocols were used for PfTRAP sub-
domains and mutants.
Binding of PfTRAP ECD and subdomains to HepG2 cells
1 × 105HepG2 cells were seeded in each well in a 96 well
cell culture plate and were allowed to grow for 24 h.
Media were discarded and cells were fixed with 4% (w/v)
paraformaldehyde in PBS for 10 min. Fixed cells were
washed and blocked with 2% BSA for two hours. Cells
were incubated with equimolar (250 nmoles) amounts of
PfTRAP ECD and its subdomains for one hour. Cells were
washed and incubated with PfTRAP ECD antibody raised
in rabbit followed by incubation with HRP conjugated
anti-rabbit antibody. Binding was detected at 490 nm
using OPD as substrate.
Binding assay of PfTRAP ECD with hepatocytes (HepG2 
cells and Huh-7 cells) and kidney cells (HEK 293 cells)
Hepatoma cells (HepG2 cells, Huh-7 cells) and HEK 293
cells (kidney cell line) at a confluency of 60–70% were
dislodged using an enzyme free dissociation buffer (Gibco
Life Sciences). Cells were washed in PBS and viability
assay was performed to check for the percentage cell via-
bility. FACS analysis was performed with hepatocytes and
kidney cells HEK 293 cells. From 90–95% viable cell pop-
ulation, 1 × 106 cells were added to each microfuge tubes
and washed thrice in FACS buffer and suspended in 50 µl
of FACS buffer (PBS, pH 7.4). Cells were then incubated
in FACS buffer supplemented with 1% BSA and incubated
on ice for one hour. Biotinylated PfTRAP ECD protein
(prepared using Pierce reagent Sulfo-NHS LC-LC Biotin)
was added in equimolar amounts to each tube and
allowed to bind with cells for one hour on ice. The cells
were washed three times with FACS buffer, and streptavi-
din-PE (Calbiochem) was added to each tube at a dilution
of 1: 2000. It was allowed to incubate for one hour on ice
in dark. The unbound dye was washed with FACS buffer
and stained cells were fixed in PBS containing 0.1% para-
formaldehyde. The number of stained cells were counted
using FACS and the mean value of stained cells was
obtained using FACS analysis software. Stained cells alone
and biotinylated-BSA bound to cells were used as controls
in these experiments.
Site-directed mutagenesis of PfTRAP ECD
Single site mutants of PfTRAP ECD were constructed using
the Quick-change site directed mutagenesis kit from Strat-
agene, USA. The mutants were generated using primers
shown in Table 1 and Table 2. Mutations were confirmed
by automated DNA sequencing. The expression profile of
the mutants was analyzed using HEK 293 cell transfection
and western blot analysis of post-transfection media in
the mammalian system.
HepG2 cell binding of PfTRAP ECD and its mutants
HepG2 cells were cultured in complete DMEM at 37°C in
a humidified CO2 incubator. 1 × 105 cells were seeded in
a 96-well cell-culture plate and were allowed to grow for
24 h. HepG2 cells were fixed with 4% (w/v) paraformal-
dehyde for 10 min at room temperature and blocked with
2% BSA for two hours at room temperature. Equal
amounts of PfTRAP ECD and its mutants were incubated
with HepG2 cells for one hour and bound proteins were
quantified using anti-PfTRAP antibodies. Wild type
PfTRAP ECD was used as positive and quantitative control
for the binding of mutant proteins to HepG2 cells.
Preparation of HepG2 and HEK 293 extracts
HepG2 cells and HEK 293 cells were scraped from the
monolayer culture flasks using enzyme free cell dissocia-
tion buffer (Gibco). Cells were washed with PBS to get rid
of any other contaminant elements. Washed cells were
lysed using Down's homogenizer and the cell extracts
were solubilized in 250 mM (final concentration) n-octyl-
beta-D-glucopyranoside buffer. The extracts were further
Table 1: Sequence of oligos used for site directed mutagenesis of 
PfTRAP
P18 gTTgTTATATTAACAgCTggAATTCCAgATAgT
P19 ACTATCTggAATTCCAgCTgTTAATATAACAAC
P20 AgATTTCTTgTAggTggTCATCCATCAgATggT
P21 ACCATCTgATggATgACCACCTACAAgAAATCT
P22 CCATCAgATggTAAAggTAACTTgTATgCTgAT
P23 ATCAgCATACAAgTTACCTTTACCTTTACCATCTgATgg
P24 gTTTgggACgAATgggCTCCATgTAgTgTAACT
P25 AgTTACACTACATggAgCCCATTCgTCCCAAAC
P26 TgTggAgAAgAAAgAgg TCCTCCAAAATgggAA
P27 TTCCCATTTTggAggACCTCTTTCTTCTCCACA
P28 gATCAACCTAgACCAggAggAgATAATTCTTCT
P29 gACAgAAgAATTATCTCCTCCTggTCTAggTTg
P30 AgAAATATTCCATATgCACCATTACCTCCAAAA
P31 TTTTggAggTAATggTgCATATggAATTCT
P32 AgAAAATATAACgATgCTCCAAAACATCCTgAAAgg
P33 CCTTTCAggATgTTTTggAgCATCgTTATATTTTCT
Table 2: Oligos used in the sets of forward and reverse primers 
to generate mutations in the PfTRAP polypeptide.
Forward Primer Reverse Primer Residue mutated
P12 P13 C42G
P14 P15 C55G
P16 P17 T131A
P18 P19 D162A
P20 P21 C205G
P22 P23 C212G
P24 P25 S251A
P26 P27 S285G
P28 P29 R307G
P30 P31 S416A
P32 P33 T470AMalaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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ultracentrifuged at 100,000 g using 60Ti (Beckmann)
rotor to remove insoluble matter.
Phosphorylation of PfTRAP and its fragments by HepG2 
cell extracts
PfTRAP ECD, the A-domain and the A+RII domains (2–5
µg) were incubated with HepG2 or HEK 293 whole cell
extracts in the presence of ATP at 37°C for 30 min. These
PfTRAP fragments were immunoprecipitated using poly-
clonal anti-PfTRAP antibodies that had been pre-
adsorbed on protein A Sepharose beads. Beads were
washed in PBS supplemented with 50 mM n-octyl-β-D-
glucopyranoside and 500 mM NaCl. The sample was
again washed in PBS thrice, boiled and resolved by SDS-
PAGE. PfTRAP protein bands were cut and sent for LC-
MS/MS analysis. Sample containing [γ-32P] ATP in gels
were dried and phosphorylation was detected by autora-
diography. HepG2 cells extract alone was taken as a nega-
tive control and PfTRAP alone with ATP was taken as a
nonspecific and autophosphorylation control.
Detection of PfTRAP phosphorylation using 
phosphospecific antibodies
PfTRAP ECD protein was incubated with whole cell
extract of HepG2 and HEK 293 cells and in presence of
cold ATP at 37°C for 30 min. The reaction mixture was
immunoprecipitated using anti-PfTRAP antibody pre-
adsorbed on protein A-sepharose beads. Samples were
boiled and resolved on SDS-PAGE. Phosphorylation of
PfTRAP was detected using phosphospecific antibodies
against serine, threonine and tyrosine residues. Negative
controls of HepG2 cells extract (with ATP without
PfTRAP) and PfTRAP (with ATP without HepG2 cell
extract) were used in these experiments.
Binding of PfTRAP to tyrosine kinases
HepG2 cell membrane extracts were incubated with 5 µg
of purified PfTRAP ECD for 30 min at 4°C in the presence
of protease inhibitor cocktail and ATP. To determine the
molecule(s) interacting with PfTRAP ECD, the mixture
was immunoprecipitated using anti-PfTRAP antibody pre-
adsorbed on beads. The beads were then washed in PBS
supplemented with 50 mM n-octyl-β-D-glucopyranoside
and 500 mM NaCl, and samples were boiled, resolved on
12% SDS-PAGE. Presence or absence of tyrosine kinases
was detected using specific antibodies against c-Src, Grb2,
Lyn and Lck and CrkL. Similar experiments with cytoplas-
mic and membrane extracts were performed to detect any
serine and threonine kinase interactors.
Phosphorylation of PfTRAP with tyrosine kinases proteins
Antibodies coupled to protein A beads were used to pull
down CrkL, Lck, and Lyn from HepG2 membrane
extracts. The PfTRAP ECD protein (20 µg) was incubated
with above beads in the presence of [γ-32P] ATP at 37°C
for 1 hr. PfTRAP was eluted from the mixture using 1M
NaCl, immunoprecipitated using anti-PfTRAP antibodies,
resolved on SDS-PAGE and detected by autoradiography
after two days of exposure.
Results
PfTRAP binding to hepatocytes
PfTRAP ECD and its subdomains were expressed in mam-
malian expression system and recombinant proteins were
purified from media using Ni-ion chelating affinity chro-
matography and gel filtration chromatography. As shown
in Figure 1a, recombinant PfTRAP protein and its frag-
ments migrated as monomers and were of very high purity
(Figure 1b). The recombinant proteins (ECD, the A-
domain and the A+RII domains) were biotinylated and
were assessed for their ability to bind to HepG2 cells by
ELISA and FACS based assays. As shown in Figure 2a,
these proteins bound to HepG2 cells with differential
degree of binding affinity. PfTRAP ECD showed highest
level of binding in comparison to other fragments. This
binding was specific to liver cells as PfTRAP ECD bound
to hepatocytes in a dose dependent manner but it failed to
bind kidney cell line HEK 293 cells (Figures 2b and 2c).
Asp162, Cys205 and Arg307 are important for PfTRAP-
HepG2 binding
To identify amino acid residues involved in interaction of
PfTRAP to HepG2 cells, different PfTRAP mutants were
constructed (Figure 3a) and the mutant proteins were
purified to homogeneity by protocols described for the
wild type protein (data not shown). These mutants were
generated based on modeled structure of PfTRAP [20].
The modeling data suggested that Cys205 and Cys 212
were likely to be exposed on the surface of PfTRAP and
Cys 43 and Cys 235 were likely to be linked by a disulfide
bond.
The modeling suggested that T131 may be in an exposed
loop, while D162 may be part of MIDAS motif. Mutants
of T131 and D162 have been previously shown to affect
sporozoite infectivity to salivary gland and liver cells [14].
A mutant R307 was also generated as it is part of RGD
motif that has been shown to be involved in integrin
interactions [21,22]. Purified mutants and wild type ECD
were incubated with hepatocytes and their binding ability
was assessed by ELISA assays described previously [20]. As
shown in Figure 3c, two mutants C205-A and D162-A
showed ~71 and ~70% reduced binding to HepG2 cells in
comparison to wild type PfTRAP ECD. Mutants C43 and
C55 (in A-domain) showed reduced binding by up to
~32% and 54% respectively. Intriguingly, arginine 307,
which is part of conserved RGD motif and for which no
specific biological significance in PfTRAP has so far been
documented, appeared important for TRAP binding to
HepG2 cells. Mutation of R307, which remains conservedMalaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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(a). Gel-filtration analysis of recombinant TRAP ECD and subdomains Figure 1
(a). Gel-filtration analysis of recombinant TRAP ECD and subdomains. Ni-affinity-purified recombinant PfTRAP A domain, 
A+RII domain, A+RII+RGD domain and ECD expressed in HEK 293 cell migrate on a gel-filtration columns (GPC) as mono-
mers. (b). SDS-PAGE of TRAP subdomains under reducing conditions. The mammalian cell-expressed and purified PfTRAP A 
domain (lane 1), A+RII domain (lane 2), A+RII+RGD domain (lane 3) and ECD (lane 4) migrate at a molecular mass of approx. 
33, 36, 38 and 70 kDa under reducing conditions.Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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(a). Binding of TRAP A domain, A+RII domain and ECD to HepG2 cells Figure 2
(a). Binding of TRAP A domain, A+RII domain and ECD to HepG2 cells. HepG2 cells (approx. 1 × 105) cells were seeded in 96 
well cell culture plates and incubated with PfTRAP fragments in equimolar amounts. Binding was evaluated through ELISA. 
Results are the mean ± SD of n = 3 experiments. (b). Binding specificity of PfTRAP ECD with hepatoma cell lines. HEK 293 
(Kidney cell line), Huh-7 and HepG2 (hepatoma cell lines) cells were incubated with biotinylated PfTRAP ECD. Binding was 
evaluated through a flow cytometry analysis using Streptavidin-PE. Results are the mean ± SD of n = 3. (c) (i, iii and v) Control 
FACS data with unstained (black), stained (light grey) and Biotinylated BSA (dark grey) using HepG2 cells, Huh-7 cells and HEK 
293 kidney cell lines respectively. (ii, iv and vi) FACS data to evaluate binding of PfTRAP ECD to HepG2 cells, Huh-7 cells and 
HEK 293 cell lines respectively with the increasing amounts of PfTRAP ECD (grey to thick black) (0.25, 0.5, 1.0 and 2.0 µg) and 
the stained cells control (thin black).Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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(a) Graphical presentation of PfTRAP mutants Figure 3
(a) Graphical presentation of PfTRAP mutants. (b) Binding of purified recombinant TRAP ECD and its mutants to heparin (100 
µg) coated on ELISA plates. They were incubated with equimolar amounts of mutants. Binding was evaluated in an ELISA based 
assay using PfTRAP antibodies. Results are the mean SD of n = 3 experiments. (c) Binding of the purified recombinant TRAP 
ECD and its mutants to HepG2 cells. HepG2 cells (approx. 105) cells were incubated with ECD and its mutants in equimolar 
amounts. Binding was evaluated in an ELISA based assay using PfTRAP antibodies. Results are the mean ± SD of n = 6 experi-
ments.Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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even in field isolates of P. falciparum TRAP, showed ~47%
reduction in binding to HepG2 cells (Figure 3c). Surpris-
ingly, most of the TRAP mutants except C55 bound to
heparin in a similar fashion as the wild type PfTRAP (Fig-
ure 3b). TRAP mutant C55 showed about 50% reduction
in heparin binding. These results suggest a potential role
for these five residues in non-heparin mediated binding to
HepG2 cells.
PfTRAP undergoes phosphorylation in presence of 
hepatocyte extract
To identify host molecules interacting with PfTRAP ECD,
we prepared membrane extracts of HepG2 cells in a mild
neutral detergent n-Octyl-β-D-glucopyranoside (USB
chemicals) and incubated it with PfTRAP ECD. The reac-
tion mixture was immunoprecipitated with anti-TRAP
antibodies and TRAP band was subjected to mass spectro-
metric analysis. These results indicated phosphorylation
of PfTRAP at multiple sites (data not shown). Autophos-
phorylation of PfTRAP was ruled out as no specific bind-
ing of ATP or autophosphorylation of PfTRAP was
observed in the presence of [γ-32  P] ATP without the
HepG2 cell extract (Figure 4a). Similar phosphorylation
results were observed when HEK 293 cell lysate was used
in place of HepG2 cell lysate (Figure 4b). To identify the
domains of PfTRAP that undergo phosphorylation, bind-
ing reactions were performed with PfTRAP subdomains in
presence of [γ-32 P] ATP and HepG2 cell lysate. The results
showed that both PfTRAP ECD and PfTRAP A+RII pro-
teins were phosphorylated while PfTRAP A-domain was
not phosphorylated. To map sites that undergo phospho-
rylation in PfTRAP, the reaction mixture containing
PfTRAP and HepG2 cell extract was immunoprecipitated
with anti-PfTRAP antibodies and the precipitated samples
were analysed by immunoblot analysis using phosphos-
pecific antibodies. As shown in Figure 5, multiple phos-
phorylation sites were observed for PfTRAP-serine,
threonine and tyrosine sites (Figure 5). A phosphorylation
reaction of PfTRAP was carried out in presence of MAPK.
As shown in Figure 5, PfTRAP got phosphorylated at mul-
tiple sites as previously seen with HepG2 cell extract.
Together these results suggested that PfTRAP probably
undergoes phosphorylation when released from the spo-
rozoites at the time of HepG2 cell invasion and kinases in
the HepG2 lysate phosphorylate the PfTRAP.
Tyrosine kinases from hepatocytes bind and mediate 
phosphorylation of PfTRAP
To identify the kinase(s) in HepG2 cell extracts that are
able to phosphorylate PfTRAP, immunoprecipitations of
reaction mixtures were carried out with anti-PfTRAP anti-
bodies. The precipitated samples were analysed for pres-
ence of Lck, CrkL Lyn, c-Src and Grb2 proteins in an
immunoblot assay using kinase specific antibodies. As
shown in Figure 6a, specific interactions of PfTRAP with
Lck, CrkL and Lyn proteins were observed, while no such
interaction could be seen with the c-Src and Grb2 pro-
teins. Since Lck, CrkL and Lyn proteins also carry kinase
domains, the phosphorylation status of PfTRAP was ana-
lysed in presence of Lck, CrkL and Lyn proteins isolated
from HepG2 cell lysate. Phosphorylation reactions
showed that PfTRAP was phosphorylated when incubated
with immunoprecipated Lck, CrkL and Lyn proteins,
while γ-32ATP alone did not phosphorylate TRAP (Figure
6b). Together, these results indicated that PfTRAP bound
to and is phosphorylated by src-family kinases.
Discussion
PfTRAP has been previously suggested to bind to HepG2
cells by interacting with sulfated proteoglycans. These
studies were carried out with multimeric or soluble aggre-
gates of recombinant PfTRAP [15,16,23,24]. In the
Recombinant PfTRAP undergoes phosphorylation in the  presence of HepG2 and HEK 293-cell lysates Figure 4
Recombinant PfTRAP undergoes phosphorylation in the 
presence of HepG2 and HEK 293-cell lysates. Recombinant 
PfTRAP fragments were incubated with HepG2 cell extract 
(a) and HEK 293 cell lysate (b) in the presence of P32 [γ 
ATP]. PfTRAP fragments were immunoprecipitated using 
anti-PfTRAP antibody and phosphorylation status was 
checked through autoradiography. (a) Lanes 1, HepG2 cell 
lysate; 2, A domain+HepG2 cell lysate; 3, A+RII+HepG2 cell 
lysate; 4, ECD+HepG2 cell lysate. ECD phosphorylation was 
also checked using recombinant MAPK (lane 6). MAPK was 
used as a control (lane 5). (b) Lanes1, HEK 293 cell lysate; 2, 
A+RII domain+ 293 cell lysate; 3, A+RII+RGD+ 293 cell 
lysate; 4, ECD+ 293 cell lysate.Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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present study, recombinant PfTRAP and its subdomains
were produced in monomeric, properly folded forms
using a mammalian expression system. The expressed
molecules were secreted out of the mammalian cells due
to the presence of signal sequence at the N-terminus of the
expressed proteins. Eleven different mutant TRAP proteins
were generated to map the amino acid residues involved
in PfTRAP binding to HepG2 cells. Results of HepG2 cell
binding assays with mammalian expressed PfTRAP and its
subdomains showed differential binding abilities. PfTRAP
ECD bound to HepG2 cells more strongly than its other
two fragments (PfTRAP A+RII and PfTRAP A). The HepG2
cell binding of TRAP was specific as neither PfTRAP ECD
nor its two recombinant subdomains were able to bind
HEK 293 cells (kidney cells). These results were in agree-
ment with a previous study where a baculo-expressed
PfTRAP A domain was expressed in monomeric forms
[20].
Amino acids involved in binding of PfTRAP proteins to
HepG2 cells were evaluated. Five mutants (D162, C205,
C55, R307 and S416) exhibited 40–70% reduced binding
to HepG2 cells. Specifically, the reduced binding of R307
(a part of the RGD triplet) indicates that this conserved
sequence plays an important role in binding of PfTRAP to
HepG2 cells via yet unidentified receptor(s) on liver cells.
Surprisingly, the-T131A mutant that has been earlier
shown to be important for hepatocyte invasion and sali-
vary gland infection in mosquitoes [14,25] showed only
~17% reduction in HepG2 cell binding in this study in
comparison to wild type. The results of site-directed muta-
genesis experiments in this paper thus suggested that
amino acid residues other than those present in RII region
play an important role in TRAP-HepG2 cell interaction.
These mutants were also analysed for heparin binding,
where no significant reduction in binding was observed.
Together, these results suggest that PfTRAP binds to
HepG2 cells using multiple modes; both heparin and
non-heparin mediated interactions play roles in mediat-
ing TRAP interaction to HepG2 cells. Similar multiple
interactions have been reported for a number of proteins
involved in cell-cell attachment [26]. For example, extra-
cellular matrix protein fibronectin simultaneously binds
to heparin sulfate proteoglycans of syndecans and one or
more integrins to induce cell spreading and focal adhe-
sion formation [27]. Also a recent study showed that the
extracellular domains of proteoglycans could bind to the
protein ligands independent of heparin sulfate chains
[28]. In the present study, an arginine residue (R281) in
the RxRKR motif was also mutated, but the mutant pro-
tein failed to get secreted in the supernatant raising ques-
tion about the misfolding of TRAP mutant molecule as
suggested by Tossavainen and coworkers [29].
In silico analysis of TRAP from all the Plasmodium species
revealed that TRAP molecules contain conserved PxxP
motifs and many potential phosphorylation sites (Table
3). This suggests possible roles for TRAP in cell signaling
once the sporozoite has entered liver cells. The phosphor-
ylation status of PfTRAP and its subdomains was probed
in presence of HepG2 cell extracts. TRAP A+RII and ECD
are readily phosphorylated, while PfTRAP A-domain is
not. The phosphorylation occurs at multiple sites that
include serine, threonine and tyrosine residues. An inter-
action of PfTRAP was observed with Lyn, Lck and CrkL
kinases, which are all able to phosphorylate TRAP. Taken
together, TRAP binding, mutagenesis and phosphoryla-
tion data clearly suggest new roles for TRAP during sporo-
zoite invasion of liver cells.
Recombinant PfTRAP ECD is phosphorylated at multiple res- idues Figure 5
Recombinant PfTRAP ECD is phosphorylated at multiple res-
idues. PfTRAP ECD was either incubated with HepG2 cell or 
HEK 293 cell lysate and immunoprecipitated using PfTRAP 
antibodies. Phosphorylation status was analyzed by western 
blotting using monoclonal antibodies against phosphorylated 
serine threonine and tyrosine (a, b and c). Lanes 4 and 5 
show the phosphorylated PfTRAP ECD in presence of HEK 
293 and HepG2 cell lysate respectively. HepG2 lysate alone 
(lane 1, panels a, b and c), HEK293 lysate alone (lanes 2 of a, 
b and c) were taken as controls. Autophosphorylation of 
ECD was also analyzed (lane 3, panels a, b and c) and none 
was observed.Malaria Journal 2008, 7:63 http://www.malariajournal.com/content/7/1/63
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Conclusion
Results presented in this study show that PfTRAP is a mul-
tifaceted molecule that plays important roles in sporo-
zoite binding to HepG2 cells and possibly in signal
transduction. At present, it is difficult to say whether the
modification of PfTRAP occurs while it is still on the spo-
rozoite surface (thereby supporting the sporozoite activa-
tion model of transmigration) [30-32] or once it has been
shed along with heparan sulfate and localized into the
cytoplasm of the host cell. However, these observations
open new avenues for investigating the role of PfTRAP
during the transmigration of sporozoite through the host
cells or during the homing of sporozoites inside the
HepG2 cells.
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(a) Recombinant PfTRAP interacts with tyrosine kinase proteins Figure 6
(a) Recombinant PfTRAP interacts with tyrosine kinase proteins. HepG2 cell membrane extract were incubated with PfTRAP 
ECD. The complex was immunoprecipitated using PfTRAP antibodies, followed by western blot analysis using monoclonal anti-
bodies against Lyn (i) (lane 2), Lck (ii) (lane 4), CrkL (iii) (lane 6). To check nonspecific interaction, HepG2 cell membrane 
extract alone was immunoprecipitated using PfTRAP antibodies (Lane 1, 3 and 5). (b) Recombinant PfTRAP is phosphorylated 
in the presence of CrkL, Lck and Lyn proteins. Lck (lane 2), Lyn (lane 4) and CrkL (lane 6) proteins were immunoprecipitated 
from HepG2 membrane extract and PfTRAP was incubated with the complex in the presence of γ33 ATP. PfTRAP was immu-
noprecipitated from the mixture and the phosphorylation was analyzed using autoradiography.
Table 3: PxxP sequence motifs in Plasmodium TRAP C-terminal regions
PfTRAP RNIPYSPLPP; PKHPER
PbTRAP RDCPPKP; PVIPIK; PDVPVK; PILPIK; PEIPSK
PyTRAP PSNPNK; RDCPQIP; PVIPNK; RRNPNKP; PIIPQK; KDEPEIP
PvTRAP PWDP; PLPP
PkTRAP PVPPTVP; PENPENP
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